Solid tumors are heterogeneous with an immunosuppressive tumor microenvironment, but that is not slowing the search to treat the most difficult, recalcitrant cases ...
Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and Ramsay Hospital Research Foundation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results